ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2102

Hyaluronic Acid Synthesis Inhibition Blocks Nephritis and Extends Lifespan in Mice Prone to Lupus

Abel Suarez-Fueyo1, Seung-Ki Kwok2, Kayaho Maeda3 and George C Tsokos4, 1Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA, 2Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul., Seoul, Korea, Republic of (South), 3Rheumatology, Department of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA, 4Division of Rheumatology, Department of Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, Boston, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: cell modulation and systemic lupus erythematosus (SLE), T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Lupus Erythematosus – Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Hyaluronic acid (HA) is a component of the extracellular matrix and is known to be involved in cancer biology. Although evidence suggests that HA plays a role in the expression of kidney pathology in patients with SLE, its function is not fully understood. T cells from patients with SLE express increased amounts of CD44 to which HA binds inducing T cell polarization, adhesion, and migration (J Immunol. 2007, 178:1938-47). In this study, we asked how HA contributes to the expression of lupus pathology and whether it can be targeted therapeutically.

Methods: We analyzed HA expression in kidneys from patients with SLE and a lupus-prone MRL/lpr mice, by using immunohistochemistry. Peripheral blood mononuclear cells (PBMC) from healthy donors were stimulated with anti-CD3/CD28 in the presence or not of HA. 4-Methylumbelliferone (4-MU), an HA synthase inhibitor, was orally administrated to male MRL/lpr starting at the age of 3 months (prevention) or 5 months of age (treatment). In addition, in a third group, 4-MU was administered at the age of 3 months and discontinued at the age of 5 months. At the end of the treatment tissues (kidney and skin) were evaluated by immunohistochemestry, spleen, lymph node and kidney cells were evaluated by flow cytometry.

Results: Kidneys from MRL/lpr and patients with SLE displayed increased accumulation of HA compared to control tissues coinciding with the accumulation of immune cells. MRL/lpr mice which received 4-MU at 3 months of age did not develop any organ inflammation, but discontinuation of treatment resulted in late disease (proteinuria, kidney and skin inflammation) development. Treatment of 5 months old mice that already developed disease halted further progression of the disease with minimal reversal of tissue pathology. Treatment with 4-MU led to increased proportions of Tregs and reduced double negative (DN)T cells, Th17, and Th1 cells both in the spleen and the kidney. Exposure of PBMC from healthy donors to low molecular weight HA in vitro while stimulated with anti-CD3/CD28 led to the expansion of DNT cells.

Conclusion:

HA expression is increased in tissues in patients with SLE and lupus-prone mice and probably enable the homing and activation of CD44 positive T cells. Inhibition of HA synthesis prevents disease development but fails to reverse established pathology. In addition, HA promotes the generation of CD4–CD8–CD3+ cells which are known to contribute to lupus immunopathology. The development of drugs which prevent the entrance and activation of T cells to tissues should represent novel approaches to prevent relapses in patients with SLE.


Disclosure: A. Suarez-Fueyo, None; S. K. Kwok, None; K. Maeda, None; G. C. Tsokos, None.

To cite this abstract in AMA style:

Suarez-Fueyo A, Kwok SK, Maeda K, Tsokos GC. Hyaluronic Acid Synthesis Inhibition Blocks Nephritis and Extends Lifespan in Mice Prone to Lupus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/hyaluronic-acid-synthesis-inhibition-blocks-nephritis-and-extends-lifespan-in-mice-prone-to-lupus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hyaluronic-acid-synthesis-inhibition-blocks-nephritis-and-extends-lifespan-in-mice-prone-to-lupus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology